At Invizius we are developing products to treat diseases driven by excessive activation of the patient's complement system.

Our first product, H-Guard® Priming Solution, is designed to prevent the serious complications caused by haemodialysis on patients with kidney failure. H-Guard is now in clinical development and alongside we are running a patient stratification study to determine the best patients to target for treatment.

Our second product (INV-201) is designed to prevent peritoneal fibrosis among ESRD patients on peritoneal dialysis, making the treatment more durable. This will improve patient outcomes, reduce healthcare costs, and increase profitability for dialysis equipment manufacturers.

We are researching a number of other therapeutic areas for further development of our PspCN complement regulation platform.